ANT-GROUP
20.9.2022 02:25:47 CEST | Business Wire | Press release
Nike today announced that it has joined Ant Group’s Green Energy Initiative and launched an official mini program on Alipay, the leading digital open platform, to encourage more consumers to recycle worn-out shoes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220919005601/en/
Students play basketball on Nike Grind court (Photo: Business Wire)
Chinese consumers can search the mini program “Recycle-A-Shoe” in the Alipay app and have worn-out Nike shoes collected for recycling. The shoes will then be dismantled and re-processed to make sustainable sport courts through Nike Grind technology. By doing so, consumers will receive virtual green energy points in Alipay Ant Forest, a green mini program. These green energy points can be used to support tree planting, ecological restoration or bio-diversity conservation projects.
“In China, Nike continues to strive toward its goal of ‘Move to Zero’ and encourages the public to take part in environmental protection. The innovative cooperation with Ant Group allows Nike’s Recycle-A-Shoe program to reach more consumers through digital solutions on the Alipay platform and incorporates Nike’s sustainability efforts into daily life, which is our long-term commitment,” said Stanley Chang, Vice President of Operations and Logistics of Nike Greater China.
“In the face of increasing challenges brought on by climate change, the private sector needs to encourage more environmental-friendly actions among consumers while committing themselves to reducing carbon emission in their business operations. We are delighted to partner with Nike to promote low carbon actions and better protect the environment through innovative solutions in recycling,” said Cheng Jiang, General Manager of Social Good Department, Ant Group.
Nike’s global “Recycle-A-Shoe” program has been active for 30 years. More than 30 million pairs of worn-out shoes and over 120 million pounds of footwear factory materials have been recycled and transformed into innovative sports products, such as basketball courts, soccer fields, running tracks, yoga equipment and interior decoration.
Launched in 2016, Alipay Ant Forest is a green initiative that encourages users to adopt low carbon activities in their daily life, which has attracted over 650 million participants since its inception. Users can gain green energy points for low carbon actions, including biking to work instead of driving and paying electricity bills online instead of offline.
Ant Group’s Green Energy Initiative, which features green energy points in Alipay Ant Forest, is open to brands that would like to offer their customers more incentives to take green actions. As of August 2022, the initiative has attracted participation from more than 500 brands across multiple sectors including travel, packaging and home appliance manufacturing.
About Move to Zero
In its commitment to the long-term plan of sustainable development, Nike launched "Move to Zero" in 2019 with the aim of operating with zero carbon emissions and zero waste. This initiative has been implemented across all aspects of design, manufacturing and transportation. Significant progress has also been made in Nike moving closer to its ambitious goal of “Move to Zero”. In September (2022), Nike announced the launch of the CLC Wind Runner Project in the China Logistics Center. After its completion and implementation in early 2023, the Nike China Logistics Center will be operating with 100% renewable energy. In regard to sustainable product innovation, Nike has launched a subversively innovative platform - Nike Forward, which will bring great changes to the apparel industry.
About Alipay
In the evolving digital era, Alipay has transformed from a payment tool of public trust to an open platform for businesses, institutions, service providers, and other partners. Business partners in various industries utilize Alipay to offer consumers a safe and convenient payment experience. Through digital operation, business partners can communicate and provide various commercial and daily life digital services for their clients via Alipay mini programs, lifestyle accounts, and IoT, along with other tools available. Currently, there have been over 80 million businesses serving more than 1 billion consumers via Alipay’s open platform services.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220919005601/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
